Table 1. Model Parameters for Alternative Model Estimation of Vaccine-Averted COVID-19 Cases.
| Parameter | Mean (95% CI) | Source |
|---|---|---|
| Vaccine effectiveness by vaccine type | ||
| BNT162b2 | ||
| Between first and second dose | 0.52 (0.3-0.68) | Polack et al,6 2020 |
| Weeks after second dose | ||
| ≤17 | 0.95 (0.90-0.98) | Polack et al,6 2020 |
| >17 | 0.77 (0.67-0.84) | Self et al,8 2021 |
| mRNA-1273 | ||
| Between first and second dose | 0.82 (0.74-0.87) | Pilishvili et al,21 2021 |
| Weeks after second dose | ||
| ≤17 | 0.94 (0.89-0.97) | Baden et al,5 2021 |
| >17 | 0.92 (0.87-0.96) | Self et al,8 2021 |
| Ad26.COV2.S | ||
| After first dose | 0.66 (0.55-0.75) | Sadoff et al,7 2021 |
| Subclinical fraction of SARS-CoV-2 infection by age group | ||
| <12 | 0.47 (0.32-0.62) | Sah et al,22 2021 |
| 12-17 | 0.47 (0.32-0.62) | Sah et al,22 2021 |
| 18-49 y | ||
| 18 y | 0.47 (0.32-0.62) | Sah et al,22 2021 |
| 19-49 y | 0.32 (0.22-0.44) | Sah et al,22 2021 |
| 50-64 y | ||
| 50-59 y | 0.32 (0.22-0.44) | Sah et al,22 2021 |
| 60-64 y | 0.20 (0.13-0.29) | Sah et al,22 2021 |
| ≥65 | 0.20 (0.13-0.29) | Sah et al,22 2021 |